Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The Value of Early Depth of Response in Predicting Long-Term Outcome in EGFR-Mutant Lung Cancer.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer - 1 Jun 2018

Lee Chee Khoon, Lord Sally, Marschner Ian, Wu Yi Long, Sequist Lecia, Rosell Rafael, Fukuoka Masahiro, Mitsudomi Tetsuya, Asher Rebecca, Davies Lucy, Gebski Val, Gralla Richard, Mok Tony, Yang James Chih-Hsin

Abstract excerpt

INTRODUCTION: Traditionally, marked tumor shrinkage has been assumed to portend better outcome. We investigated whether depth of tumor response was associated with improved survival outcomes in advanced EGFR-mutant NCLC. METHODS: Individual patient data from randomized trials (EURTAC, IPASS, ENSURE, LUX-Lung 3, and LUX-Lung 6) were used. The association of depth of response with progression-free survival (PFS)...

Topics

Join the communities discussing this publication.

Disease-Free Survival
ErbB Receptors
Lung Neoplasms
Mutation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Protein Kinase Inhibitors

Randomized Controlled Trials as Topic

Treatment Outcome

Source

Identifiers

PMID: 29580950
DOI: 10.1016/j.jtho.2018.03.010

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The Value of Early Depth of Response in Predicting Long-Term Outcome in EGFR-Mutant Lung Cancer.PMID 29580950Read ↗

Best Response According to RECIST During First-line EGFR-TKI Treatment Predicts Survival in EGFR Mutation-positive Non-Small-cell Lung Cancer Patients.Semantic proximity Read ↗

Timing in combination with radiotherapy and patterns of disease progression in non-small cell lung cancer treated with EGFR-TKI.Semantic proximity Read ↗

Survival outcome assessed according to tumor response and shrinkage pattern in patients with EGFR mutation-positive non-small-cell lung cancer treated with gefitinib or erlotinib.Semantic proximity Read ↗

The local therapy strategy in progressive ALK or EGFR non-small cell lung cancerSemantic proximity Read ↗

Delay of treatment change after objective progression on first-line erlotinib in epidermal growth factor receptor-mutant lung cancer.Semantic proximity Read ↗

Early radiographic response to epidermal growth factor receptor-tyrosine kinase inhibitor in non-small cell lung cancer patients with epidermal growth factor receptor mutations: A prospective study.Semantic proximity Read ↗

Survival outcome of tyrosine kinase inhibitors beyond progression in association to radiotherapy in oligoprogressive EGFR-mutant non-small-cell lung cancer.Semantic proximity Read ↗

Volumetric Tumor Response and Progression in EGFR-mutant NSCLC Patients Treated with Erlotinib or Gefitinib.Semantic proximity Read ↗

Early Prediction of Response to Tyrosine Kinase Inhibitors by Quantification of EGFR Mutations in Plasma of NSCLC Patients.Semantic proximity Read ↗

Radiographic Versus Pathology-Integrated Response for Assessing Optimal Surgical Timing After Neoadjuvant Imatinib in Patients With Locally Advanced KIT Exon 11-Mutant GIST.Semantic proximity Read ↗

Tumor volume decrease at 8 weeks is associated with longer survival in EGFR-mutant advanced non-small-cell lung cancer patients treated with EGFR TKI.Semantic proximity Read ↗

Volume-based growth tumor kinetics as a prognostic biomarker for patients with EGFR mutant lung adenocarcinoma undergoing EGFR tyrosine kinase inhibitor therapy: a case control study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.